The Hormonal Contraceptives Market size was valued at USD 17.58 Billion in 2023 and is expected to reach USD 25.39 Billion By 2031 and grow at a CAGR of 4.70% over the forecast period of 2024-2031.
The hormonal contraceptives market refers to the universal market for pharmaceutical products that contain synthetic hormones and are used to prevent pregnancy. Hormonal contraceptives work by altering a woman's hormonal balance, primarily through the use of estrogen and/or progestin hormones, to prevent ovulation or make it difficult for sperm to reach the egg.
The hormonal contraceptives market is driven by factors such as increasing awareness of family planning, rising contraceptive prevalence rate, advancements in contraceptive technologies, and the growing need for effective birth control methods.
The desire to avoid unwanted pregnancy, as well as urbanization and user awareness, are expected to drive market expansion throughout the forecast period. According to the Department of Economic and Social Affairs' World Fertility and Family Planning 2020 study, women have fewer infants generally, yet fertility rates are high in some regions of the world. The 2030 Agenda for Sustainable Development includes targets related to family planning and fertility objectives, as well as a number of other goals to safeguard the population's health and well-being.
According to Target 3.7, by 2030, everyone will have access to family planning, informative and instructional resources, and programmers that include reproductive health in national policies and plans. As a result, improved knowledge and government activities on family planning are anticipated to result in higher demand for contraception, which is expected to grow the market. Furthermore, according to an article published by the Kaiser Family Foundation in November 2021 titled The United States Government and International Family Planning and Reproductive Health Efforts, 220 million females globally have an unmatched need for new contraception. The increased demand for contraceptives throughout the world is expected to drive the market over the projected period.
As societies become more aware of the importance of family planning and reproductive health, the demand for hormonal contraceptives has increased.
Hormonal contraceptive is considered to be more credible than condoms & sponges/diaphragms.
Pursuance to an NCBI study, only 2 out of 2,000 women walk pregnant if they have these contraceptives fairly. The growing unmet need in order to contraceptives significantly motivates. its demand to improve this supply in niche regions globally. The W.H.O., reports that approximately 24.4% of women of reproductive period in Africa have an unmatched need for modern contraception. In Latin America & the Caribbean and Asia, the unmatched need levels are 10.4 % and 10.8%, respectively. Such a large gap in demand-supply is projected to grow up the market rise during the forecast period.
Restrain
The use of these pills may be restricted due to the lack of understanding while using these long-term hormonal contraceptive pills.
Associated Side Effects May Restrain Hormonal Contraceptives Market Augmentation.
Possible side effects from its use include nausea, headache, vaginal yeast infection (thrush) and sore breasts. Hormones can cause spotting between periods or cause mood changes & reduce women's sexual desire.
Opportunity
There is a rise in healthcare expenditure by various organizations which is driving market growth.
Rising Demand for Oral Contraceptives Pill Can Be Seen as an Opportunity.
Oral contraceptive hormonal pills are likely to increase their market share due to ease of use and availability. Furthermore, several companies are focusing on new product launches and pursuing combination hormonal contraceptives, which is likely to fuel the growth of the market.
Challenge
Public mistrust of pharmaceutical companies about the safety and efficacy of hormonal contraceptives is a challenge for this market.
Limited access to education & awareness programs about contraception in some areas and communities.
Educational programmes can help raise awareness of available contraceptive techniques, allowing people to make better-educated decisions and use contraception more successfully. The purpose of this systematic evaluation is to advise national recommendations on quality family planning services by evaluating contraceptive education strategies.
The repercussions of the Russia-Ukraine conflict have been predominantly adverse, particularly felt in the European Union, Eastern Europe, the United States, and Eastern and Central Asia. This dispute has had a significant toll on the well-being and economic stability of individuals, while also inducing considerable disturbances in the realm of international trade. The probable consequences of the prolonged war and instability in Eastern Europe are projected to harm Ukraine and have long-term consequences for Russia. The war had implications on demand-supply balances, pricing pressures, the influence on import/export and trade, and short-term suggestions for the worldwide Hormonal Contraceptives Market in light of the most recent conflict update and worldwide reactions.
Due to the war between Ukraine and Russia, the whole world had been affected, be it business or any sector. Ukraine is a sparsely populated country and due to the attack of that Russia After that, there has been a significant decline in its population, due to the migration of people to other nations, so its market growth will be less in Ukraine. The Hormonal Contraceptives Market will see a jump in market growth from 3.5 to 4.1 % after the conflict stabilises.
Impact of COVID-19
A recent report by CHAI and RHSC highlights that the public-sector contraceptive market contracted by 9% in 2021 due to the impact of the COVID-19 pandemic and funding challenges. Decreased procurement of injectables and oral contraceptives drove the decline, reaching $265 million across 84 countries. Market volumes dropped by 16%, however, long-acting methods such as implants and hormonal IUDs saw a growth in their share. Stakeholders recognize that 2021 was an exceptionally difficult year for contraceptive procurement, with COVID-19 causing funding disruptions, supply chain delays, and increased freight costs.
Despite the persistent disruptions caused by COVID-19 to crucial services, supply chains, and funding for sexual and reproductive health, our community has persevered diligently to mitigate the impact of these challenges, the demand for safe, affordable, and quality-assured contraception is expected to surge in low- and middle-income countries. This will drive the need for increased funding for procuring contraceptives and necessitate continuous efforts to enhance the affordability and accessibility of family planning services.
By Product
Transdermal Patches
Oral Contraceptive Pills
Emergency Contraceptive Pills
Injectable Birth Control
Vaginal Rings
By Hormones
Combined Hormonal Contraceptive
Progestin-Only Contraceptive
By Age Group
14-23 Years
24-35 Years
36-45 Years
Above 45 Years
By End User
Household
Hospitals
Clinics
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
North America: North America dominated the worldwide industry in 2022, accounting for 43.6% of total sales and will continue to dominate over the projection period, it is predicted to keep its leadership position by increasing at the CAGR of more than 4.5%. This is due to the presence of significant factors, greater sexual health awareness, and a high number of unintended pregnancies. According to the American College of Obstetricians and Gynecologists, nearly 99.2% of sexually active women in the United States use contraception, with roughly 88.4% prefer reversible options such as IUDs, implants, vaginal rings, patches, and others.
Asia-Pacific & Europe: During the projection period, the Asia-Pacific area is expected to have growth with a significant CAGR. The primary drivers complementing regional growth include a large target population, an increase in investment by important businesses, the launch of innovative contraceptive technologies for females, and a fast-rising economy. The European regional market is expected to grow because of an increase in product introductions, favourable government reimbursement policies, and improved sexual health awareness.
The major key players are Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd, Bayer AG, Pfizer Inc., Agile Therapeutics, Cupid Ltd., Helm AG, Church & Dwight Co., Inc., Reckitt Benckiser Group PLC, Lupin Pharmaceuticals Inc. and others.
Pantarhei Bioscience -In 2021, Pantarhei Bioscience announced that the European Commission has approved the company's novel oral contraceptive Estelle. Contraceptives can be sold in all European countries with Estelle's clearance.
AstraZeneca: - In 2021, The Medicines and Healthcare Products Regulatory Agency (MHRA) released guidance on AstraZeneca's COVID-19 vaccine, stating that blood clots were unlikely to develop. According to the guidelines, healthcare practitioners should give safe and effective contraceptive treatment, such as the combination pill, transdermal patch, and vaginal ring, to users who are at high risk of thrombosis when using CHC.
Mithra Pharmaceuticals: Mayne Pharma Group Limited and Mithra Pharmaceuticals announced the FDA's clearance of the oral contraceptive NEXTSTELLIS in 2021.
| Report Attributes | Details |
| Market Size in 2023 | US$ 17.58 Bn |
| Market Size by 2031 | US$ 25.39 Bn |
| CAGR | CAGR of 4.70% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Transdermal Patches, Oral Contraceptive Pills, Emergency Contraceptive Pills, Injectable Birth Control, and Vaginal Rings) • By Hormones (Combined Hormonal Contraceptive and Progestin-Only Contraceptive) • By Age Group (14-23 Years, 24-35 Years, 36-45 Years, and Above 45 Years) • By End User (Household, Hospitals, and Clinics) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa]), Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd, Bayer AG, Pfizer Inc., Agile Therapeutics, Cupid Ltd., Helm AG, Church & Dwight Co., Inc., Reckitt Benckiser Group PLC, Lupin Pharmaceuticals Inc. |
| Key Drivers | • As societies become more aware of the importance of family planning and reproductive health, the demand for hormonal contraceptives has increased. • Hormonal contraceptive is considered to be more credible than condoms & sponges/diaphragms. |
| Market Opportunities | • There is a rise in healthcare expenditure by various organizations which is driving market growth. • Rising Demand for Oral Contraceptives Pill Can Be Seen as an Opportunity. |
Ans. The Compound Annual Growth rate for Hormonal Contraceptives Market over the forecast period is 4.5%.
Ans. USD 23.89 Billion is the projected Hormonal Contraceptives Market size of the market by 2030.
Ans. North America is the fastest-growing region of the Hormonal Contraceptives Market.
Ans. The major key players are Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd, Bayer AG, Pfizer Inc., Agile Therapeutics, Cupid Ltd., Helm AG, Church & Dwight Co., Inc., Reckitt Benckiser Group PLC, Lupin Pharmaceuticals Incand other key players mentioned in the report.
Ans. The key drivers Rising awareness of contraceptive techniques in emerging nations, investments by major companies in developing novel devices, and supporting government actions to enhance access to products are significant market expansion.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine-Russia War
4.2 Impact of COVID-19
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Hormonal Contraceptives Market Segmentation, by Product
8.1 Transdermal Patches
8.2 Oral Contraceptive Pills
8.3 Emergency Contraceptive Pills
8.4 Injectable Birth Control
8.5 Vaginal Rings
9. Hormonal Contraceptives Market Segmentation, by Hormones
9.1 Combined Hormonal Contraceptive
9.2 Progestin-Only Contraceptive
10. Hormonal Contraceptives Market Segmentation, by Age Group
10.1 14-23 Years
10.2 24-35 Years
10.3 36-45 Years
10.4 Above 45 Years
11. Hormonal Contraceptives Market Segmentation, by End User
11.1 Household
11.2 Hospitals
11.3 Clinics
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Hormonal Contraceptives Market by Country
12.2.2 North America Hormonal Contraceptives Market by Product
12.2.3 North America Hormonal Contraceptives Market by Hormones
12.2.4 North America Hormonal Contraceptives Market by Age Group
12.2.5 North America Hormonal Contraceptives Market by End User
12.2.6 USA
12.2.6.1 USA Hormonal Contraceptives Market by Product
12.2.6.2 USA Hormonal Contraceptives Market by Hormones
12.2.6.3 USA Hormonal Contraceptives Market by Age Group
12.2.6.4 USA Hormonal Contraceptives Market by End User
12.2.7 Canada
12.2.7.1 Canada Hormonal Contraceptives Market by Product
12.2.7.2 Canada Hormonal Contraceptives Market by Hormones
12.2.7.3 Canada Hormonal Contraceptives Market by Age Group
12.2.7.4 Canada Hormonal Contraceptives Market by End User
12.2.8 Mexico
12.2.8.1 Mexico Hormonal Contraceptives Market by Product
12.2.8.2 Mexico Hormonal Contraceptives Market by Hormones
12.2.8.3 Mexico Hormonal Contraceptives Market by Age Group
12.2.8.4 Mexico Hormonal Contraceptives Market by End User
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Hormonal Contraceptives Market by Country
12.3.1.2 Eastern Europe Hormonal Contraceptives Market by Product
12.3.1.3 Eastern Europe Hormonal Contraceptives Market by Hormones
12.3.1.4 Eastern Europe Hormonal Contraceptives Market by Age Group
12.3.1.5 Eastern Europe Hormonal Contraceptives Market by End User
12.3.1.6 Poland
12.3.1.6.1 Poland Hormonal Contraceptives Market by Product
12.3.1.6.2 Poland Hormonal Contraceptives Market by Hormones
12.3.1.6.3 Poland Hormonal Contraceptives Market by Age Group
12.3.1.6.4 Poland Hormonal Contraceptives Market by End User
12.3.1.7 Romania
12.3.1.7.1 Romania Hormonal Contraceptives Market by Product
12.3.1.7.2 Romania Hormonal Contraceptives Market by Hormones
12.3.1.7.3 Romania Hormonal Contraceptives Market by Age Group
12.3.1.7.4 Romania Hormonal Contraceptives Market by End User
12.3.1.8 Hungary
12.3.1.8.1 Hungary Hormonal Contraceptives Market by Product
12.3.1.8.2 Hungary Hormonal Contraceptives Market by Hormones
12.3.1.8.3 Hungary Hormonal Contraceptives Market by Age Group
12.3.1.8.4 Hungary Hormonal Contraceptives Market by End User
12.3.1.9 Turkey
12.3.1.9.1 Turkey Hormonal Contraceptives Market by Product
12.3.1.9.2 Turkey Hormonal Contraceptives Market by Hormones
12.3.1.9.3 Turkey Hormonal Contraceptives Market by Age Group
12.3.1.9.4 Turkey Hormonal Contraceptives Market by End User
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Hormonal Contraceptives Market by Product
12.3.1.10.2 Rest of Eastern Europe Hormonal Contraceptives Market by Hormones
12.3.1.10.3 Rest of Eastern Europe Hormonal Contraceptives Market by Age Group
12.3.1.10.4 Rest of Eastern Europe Hormonal Contraceptives Market by End User
12.3.2 Western Europe
12.3.2.1 Western Europe Hormonal Contraceptives Market by Country
12.3.2.2 Western Europe Hormonal Contraceptives Market by Product
12.3.2.3 Western Europe Hormonal Contraceptives Market by Hormones
12.3.2.4 Western Europe Hormonal Contraceptives Market by Age Group
12.3.2.5 Western Europe Hormonal Contraceptives Market by End User
12.3.2.6 Germany
12.3.2.6.1 Germany Hormonal Contraceptives Market by Product
12.3.2.6.2 Germany Hormonal Contraceptives Market by Hormones
12.3.2.6.3 Germany Hormonal Contraceptives Market by Age Group
12.3.2.6.4 Germany Hormonal Contraceptives Market by End User
12.3.2.7 France
12.3.2.7.1 France Hormonal Contraceptives Market by Product
12.3.2.7.2 France Hormonal Contraceptives Market by Hormones
12.3.2.7.3 France Hormonal Contraceptives Market by Age Group
12.3.2.7.4 France Hormonal Contraceptives Market by End User
12.3.2.8 UK
12.3.2.8.1 UK Hormonal Contraceptives Market by Product
12.3.2.8.2 UK Hormonal Contraceptives Market by Hormones
12.3.2.8.3 UK Hormonal Contraceptives Market by Age Group
12.3.2.8.4 UK Hormonal Contraceptives Market by End User
12.3.2.9 Italy
12.3.2.9.1 Italy Hormonal Contraceptives Market by Product
12.3.2.9.2 Italy Hormonal Contraceptives Market by Hormones
12.3.2.9.3 Italy Hormonal Contraceptives Market by Age Group
12.3.2.9.4 Italy Hormonal Contraceptives Market by End User
12.3.2.10 Spain
12.3.2.10.1 Spain Hormonal Contraceptives Market by Product
12.3.2.10.2 Spain Hormonal Contraceptives Market by Hormones
12.3.2.10.3 Spain Hormonal Contraceptives Market by Age Group
12.3.2.10.4 Spain Hormonal Contraceptives Market by End User
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Hormonal Contraceptives Market by Product
12.3.2.11.2 Netherlands Hormonal Contraceptives Market by Hormones
12.3.2.11.3 Netherlands Hormonal Contraceptives Market by Age Group
12.3.2.11.4 Netherlands Hormonal Contraceptives Market by End User
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Hormonal Contraceptives Market by Product
12.3.2.12.2 Switzerland Hormonal Contraceptives Market by Hormones
12.3.2.12.3 Switzerland Hormonal Contraceptives Market by Age Group
12.3.2.12.4 Switzerland Hormonal Contraceptives Market by End User
12.3.2.13 Austria
12.3.2.13.1 Austria Hormonal Contraceptives Market by Product
12.3.2.13.2 Austria Hormonal Contraceptives Market by Hormones
12.3.2.13.3 Austria Hormonal Contraceptives Market by Age Group
12.3.2.13.4 Austria Hormonal Contraceptives Market by End User
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Hormonal Contraceptives Market by Product
12.3.2.14.2 Rest of Western Europe Hormonal Contraceptives Market by Hormones
12.3.2.14.3 Rest of Western Europe Hormonal Contraceptives Market by Age Group
12.3.2.14.4 Rest of Western Europe Hormonal Contraceptives Market by End User
12.4 Asia-Pacific
12.4.1 Asia Pacific Hormonal Contraceptives Market by Country
12.4.2 Asia Pacific Hormonal Contraceptives Market by Product
12.4.3 Asia Pacific Hormonal Contraceptives Market by Hormones
12.4.4 Asia Pacific Hormonal Contraceptives Market by Age Group
12.4.5 Asia Pacific Hormonal Contraceptives Market by End User
12.4.6 China
12.4.6.1 China Hormonal Contraceptives Market by Product
12.4.6.2 China Hormonal Contraceptives Market by Hormones
12.4.6.3 China Hormonal Contraceptives Market by Age Group
12.4.6.4 China Hormonal Contraceptives Market by End User
12.4.7 India
12.4.7.1 India Hormonal Contraceptives Market by Product
12.4.7.2 India Hormonal Contraceptives Market by Hormones
12.4.7.3 India Hormonal Contraceptives Market by Age Group
12.4.7.4 India Hormonal Contraceptives Market by End User
12.4.8 Japan
12.4.8.1 Japan Hormonal Contraceptives Market by Product
12.4.8.2 Japan Hormonal Contraceptives Market by Hormones
12.4.8.3 Japan Hormonal Contraceptives Market by Age Group
12.4.8.4 Japan Hormonal Contraceptives Market by End User
12.4.9 South Korea
12.4.9.1 South Korea Hormonal Contraceptives Market by Product
12.4.9.2 South Korea Hormonal Contraceptives Market by Hormones
12.4.9.3 South Korea Hormonal Contraceptives Market by Age Group
12.4.9.4 South Korea Hormonal Contraceptives Market by End User
12.4.10 Vietnam
12.4.10.1 Vietnam Hormonal Contraceptives Market by Product
12.4.10.2 Vietnam Hormonal Contraceptives Market by Hormones
12.4.10.3 Vietnam Hormonal Contraceptives Market by Age Group
12.4.10.4 Vietnam Hormonal Contraceptives Market by End User
12.4.11 Singapore
12.4.11.1 Singapore Hormonal Contraceptives Market by Product
12.4.11.2 Singapore Hormonal Contraceptives Market by Hormones
12.4.11.3 Singapore Hormonal Contraceptives Market by Age Group
12.4.11.4 Singapore Hormonal Contraceptives Market by End User
12.4.12 Australia
12.4.12.1 Australia Hormonal Contraceptives Market by Product
12.4.12.2 Australia Hormonal Contraceptives Market by Hormones
12.4.12.3 Australia Hormonal Contraceptives Market by Age Group
12.4.12.4 Australia Hormonal Contraceptives Market by End User
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Hormonal Contraceptives Market by Product
12.4.13.2 Rest of Asia-Pacific Hormonal Contraceptives Market by Hormones
12.4.13.3 Rest of Asia-Pacific Hormonal Contraceptives Market by Age Group
12.4.13.4 Rest of Asia-Pacific Hormonal Contraceptives Market by End User
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Hormonal Contraceptives Market by Country
12.5.1.2 Middle East Hormonal Contraceptives Market by Product
12.5.1.3 Middle East Hormonal Contraceptives Market by Hormones
12.5.1.4 Middle East Hormonal Contraceptives Market by Age Group
12.5.1.5 Middle East Hormonal Contraceptives Market by End User
12.5.1.6 UAE
12.5.1.6.1 UAE Hormonal Contraceptives Market by Product
12.5.1.6.2 UAE Hormonal Contraceptives Market by Hormones
12.5.1.6.3 UAE Hormonal Contraceptives Market by Age Group
12.5.1.6.4 UAE Hormonal Contraceptives Market by End User
12.5.1.7 Egypt
12.5.1.7.1 Egypt Hormonal Contraceptives Market by Product
12.5.1.7.2 Egypt Hormonal Contraceptives Market by Hormones
12.5.1.7.3 Egypt Hormonal Contraceptives Market by Age Group
12.5.1.7.4 Egypt Hormonal Contraceptives Market by End User
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Hormonal Contraceptives Market by Product
12.5.1.8.2 Saudi Arabia Hormonal Contraceptives Market by Hormones
12.5.1.8.3 Saudi Arabia Hormonal Contraceptives Market by Age Group
12.5.1.8.4 Saudi Arabia Hormonal Contraceptives Market by End User
12.5.1.9 Qatar
12.5.1.9.1 Qatar Hormonal Contraceptives Market by Product
12.5.1.9.2 Qatar Hormonal Contraceptives Market by Hormones
12.5.1.9.3 Qatar Hormonal Contraceptives Market by Age Group
12.5.1.9.4 Qatar Hormonal Contraceptives Market by End User
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Hormonal Contraceptives Market by Product
12.5.1.10.2 Rest of Middle East Hormonal Contraceptives Market by Hormones
12.5.1.10.3 Rest of Middle East Hormonal Contraceptives Market by Age Group
12.5.1.10.4 Rest of Middle East Hormonal Contraceptives Market by End User
12.5.2. Africa
12.5.2.1 Africa Hormonal Contraceptives Market by Country
12.5.2.2 Africa Hormonal Contraceptives Market by Product
12.5.2.3 Africa Hormonal Contraceptives Market by Hormones
12.5.2.4 Africa Hormonal Contraceptives Market by Age Group
12.5.2.5 Africa Hormonal Contraceptives Market by End User
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Hormonal Contraceptives Market by Product
12.5.2.6.2 Nigeria Hormonal Contraceptives Market by Hormones
12.5.2.6.3 Nigeria Hormonal Contraceptives Market by Age Group
12.5.2.6.4 Nigeria Hormonal Contraceptives Market by End User
12.5.2.7 South Africa
12.5.2.7.1 South Africa Hormonal Contraceptives Market by Product
12.5.2.7.2 South Africa Hormonal Contraceptives Market by Hormones
12.5.2.7.3 South Africa Hormonal Contraceptives Market by Age Group
12.5.2.7.4 South Africa Hormonal Contraceptives Market by End User
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Hormonal Contraceptives Market by Product
12.5.2.8.2 Rest of Africa Hormonal Contraceptives Market by Hormones
12.5.2.8.3 Rest of Africa Hormonal Contraceptives Market by Age Group
12.5.2.8.4 Rest of Africa Hormonal Contraceptives Market by End User
12.6. Latin America
12.6.1 Latin America Hormonal Contraceptives Market by Country
12.6.2 Latin America Hormonal Contraceptives Market by Product
12.6.3 Latin America Hormonal Contraceptives Market by Hormones
12.6.4 Latin America Hormonal Contraceptives Market by Age Group
12.6.5 Latin America Hormonal Contraceptives Market by End User
12.6.6 Brazil
12.6.6.1 Brazil Hormonal Contraceptives Market by Product
12.6.6.2 Brazil Hormonal Contraceptives Market by Hormones
12.6.6.3 Brazil Hormonal Contraceptives Market by Age Group
12.6.6.4 Brazil Hormonal Contraceptives Market by End User
12.6.7 Argentina
12.6.7.1 Argentina Hormonal Contraceptives Market by Product
12.6.7.2 Argentina Hormonal Contraceptives Market by Hormones
12.6.7.3 Argentina Hormonal Contraceptives Market by Age Group
12.6.7.4 Argentina Hormonal Contraceptives Market by End User
12.6.8 Colombia
12.6.8.1 Colombia Hormonal Contraceptives Market by Product
12.6.8.2 Colombia Hormonal Contraceptives Market by Hormones
12.6.8.3 Colombia Hormonal Contraceptives Market by Age Group
12.6.8.4 Colombia Hormonal Contraceptives Market by End User
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Hormonal Contraceptives Market by Product
12.6.9.2 Rest of Latin America Hormonal Contraceptives Market by Hormones
12.6.9.3 Rest of Latin America Hormonal Contraceptives Market by Age Group
12.6.9.4 Rest of Latin America Hormonal Contraceptives Market by End User
13 Company Profile
13.1 Merck & Co., Inc.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Product/Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Teva Pharmaceuticals Industries Ltd
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Product/Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Bayer AG
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Product/Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Pfizer Inc
13.4 Company Overview
13.4.2 Financials
13.4.3 Product/Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Agile Therapeutics
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Product/Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Cupid Ltd
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Product/Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Helm AG
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Product/Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Church & Dwight Co., Inc
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Product/Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Reckitt Benckiser Group PLC
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Product/Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Lupin Pharmaceuticals Inc
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Product/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
14. Competitive Landscape
14.1 Competitive Bench marking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Smart Pulse Oximeters Market Size was valued at USD 1.73 billion in 2022, and is expected to reach USD 3.08 billion by 2030 and grow at a CAGR of 7.5% over the forecast period 2023-2030.
The Central Nervous System Treatment Market size was valued at USD 97.20 Bn in 2022 and is expected to reach USD 196.53 Bn by 2030 and grow at a CAGR of 9.2% over the forecast period of 2023-2030.
The Lancet Market size was estimated USD 1.4 billion in 2022 and is expected to reach USD 3.13 billion by 2030 at a CAGR of 10.6% during the forecast period of 2023-2030.
The Feminine Hygiene Products Market Size was valued at USD 24.1 billion in 2022 and is expected to reach USD 37.26 billion by 2030, and grow at a CAGR of 5.6% over the forecast period 2023-2030.
The Healthcare Interoperability Solutions Market Size was valued at USD 2.98 billion in 2022, and is expected to reach USD 8.38 billion by 2030 and grow at a CAGR of 13.8% over the forecast period 2023-2030.
The Conjunctivitis Treatment Market size was USD 4.18 Billion in 2022 and is expected to Reach USD 5.72 Billion by 2030 and grow at a CAGR of 4% over the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
